Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Chaobin He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8149-1264; OpenAlex author ID A5088392254. Sources: OpenAlex.

Their work

Papers
32 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2018: 1 paper · 2019: 6 papers · 2020: 12 papers · 2021: 6 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 32

  1. Anti-PD-1 blockade reverses low-intensity electric stimulation-driven pancreatic cancer progression. Last author DOI 10.3389/fimmu.2026.1793161↗
  2. Efficacy of immune checkpoint inhibitors combined with different chemotherapy in recurrent pancreatic cancer: a retrospective study. Last author DOI 10.3389/fimmu.2026.1841783↗
  3. Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation. Last author DOI 10.3389/fimmu.2025.1546242↗
  4. Efficacy of irreversible electroporation combined with immunotherapy versus irreversible electroporation alone in locally advanced pancreatic cancer: a propens… Last author DOI 10.3389/fimmu.2025.1620988↗
  5. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer [Cancer Lett. 502 (2021) 9-24]. Co-author DOI 10.1016/j.canlet.2024.216697↗
  6. An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer. Co-author DOI 10.3389/fmolb.2022.876607↗
  7. [Comparison of the efficacy of irreversible electroporation and conversional resection for locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20220415-00168↗
  8. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.12.018↗
  9. The impact of different metastatic patterns on survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.014↗
  10. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer. Co-author DOI 10.1080/2162402x.2021.1897295↗
  11. Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection. Co-author DOI 10.1155/2021/3809095↗
  12. Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irrever… Co-author DOI 10.2147/jir.s307884↗
  13. Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.2147/jir.s331023↗
  14. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs… Co-author DOI 10.1002/cam4.3119↗
  15. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Co-author DOI 10.1002/ctm2.39↗
  16. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. First author DOI 10.1002/ctm2.41↗
  17. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.bbrc.2020.02.042↗
  18. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score ma… Co-author DOI 10.1016/j.pan.2020.02.009↗
  19. Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00006↗
  20. Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessmen… Co-author DOI 10.3389/fonc.2020.00590↗
  21. A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After … Co-author DOI 10.3389/fonc.2020.00952↗
  22. SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Co-author DOI 10.3389/fonc.2020.01482↗
  23. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. Co-author DOI 10.3389/fonc.2020.01564↗
  24. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.622318↗
  25. [Combining intraoperative ultrasound-guided irreversible electroporation with chemotherapy for treating locally advanced pancreatic cancer: a clinical report o… First author DOI 10.3760/cma.j.cn112139-20200331-00270↗
  26. A feasible CT feature to differentiate focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2526↗
  27. Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. Co-author DOI 10.1155/2019/9346017↗
  28. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity sco… Co-author DOI 10.1186/s12885-019-5607-3↗
  29. Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis. Co-author DOI 10.1186/s12885-019-5744-8↗
  30. Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study. Co-author DOI 10.2139/ssrn.3266972↗
  31. A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. Co-author DOI 10.3389/fonc.2019.01197↗
  32. A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. Co-author DOI 10.7150/jca.26187↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengping Li · 24 shared papers, 2018–2026 · strength 3.48
  2. Xiaojun Lin · 14 shared papers, 2019–2021 · strength 1.97
  3. Shuxin Sun · 13 shared papers, 2019–2024 · strength 1.81
  4. Xin Huang · 13 shared papers, 2018–2024 · strength 1.74
  5. Pu Xi · 4 shared papers, 2025–2026 · strength 1.17
  6. Lingmin Jiang · 3 shared papers, 2025–2026 · strength 0.88
  7. Zehui Yao · 3 shared papers, 2025–2026 · strength 0.85
  8. Fengxiao Xie · 5 shared papers, 2020–2024 · strength 0.76
  9. Shengping Li · 2 shared papers, 2025–2026 · strength 0.60
  10. Xiang‐Ming Lao · 4 shared papers, 2018–2022 · strength 0.51
  11. Jun Wang · 4 shared papers, 2018–2024 · strength 0.48
  12. Yize Mao · 4 shared papers, 2019–2020 · strength 0.41
  13. S P Li · 2 shared papers, 2020–2022 · strength 0.33
  14. Qiang Tao · 1 shared paper, 2026 · strength 0.32
  15. Guangmei Yan · 2 shared papers, 2021–2024 · strength 0.29
  16. Jing Cai · 2 shared papers, 2021–2024 · strength 0.29
  17. Yunda Song · 3 shared papers, 2018–2020 · strength 0.29
  18. Dailei Qin · 1 shared paper, 2025 · strength 0.27
  19. Bokang Cui · 2 shared papers, 2019–2020 · strength 0.23
  20. Yu Zhang · 1 shared paper, 2019 · strength 0.14
  21. Yu Zhang · 1 shared paper, 2020 · strength 0.13
  22. Xiaofeng Lin · 1 shared paper, 2020 · strength 0.13
  23. Peng Huang · 1 shared paper, 2020 · strength 0.11
  24. Dailin Rong · 1 shared paper, 2019 · strength 0.10
  25. Qiuxia Yang · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.